Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
01 1Bachem AG
02 3Aspen Oss B.V.
03 1Ambiopharm, Inc.
04 1Aurobindo Pharma Limited
05 1BCN PEPTIDES SA
06 1CHEMI SPA
07 1Darmerica, LLC
08 13Hemmo Pharmaceuticals Pvt. Ltd
09 1MEDISCA Inc.
10 23Piramal Pharma Limited
11 1PolyPeptide Laboratories, Pvt. Ltd.
12 1Professional Compounding Centers of America
13 1SUN PHARMACEUTICAL INDUSTRIES, INC.
14 3Takeda Pharmaceutical Company LTD
15 8Takeda Pharmaceutical Company Limited
16 1Zhejiang Supor Pharmaceuticals Co., Ltd
01 2LEUPROLIDE
02 1LEUPROLIDE ACETATE
03 2Leuprolide
04 44Leuprolide Acetate
05 1Leuprorelin
06 11leuprolide acetate
01 1China
02 2India
03 1Italy
04 11Japan
05 3Netherlands
06 1Spain
07 2Switzerland
08 39U.S.A
09 1United Kingdom
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0002
Start Marketing Date : 2001-11-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0425
Start Marketing Date : 1996-04-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0471
Start Marketing Date : 2014-06-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60870-0472
Start Marketing Date : 1996-04-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11532-1451
Start Marketing Date : 1989-01-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (7.5mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 11532-1452
Start Marketing Date : 1993-04-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (11.25mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 11532-1453
Start Marketing Date : 1993-04-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (15mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 11532-1454
Start Marketing Date : 1993-04-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (7.5mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 11532-1455
Start Marketing Date : 2011-06-17
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (45mg/1.5mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 11532-1450
Start Marketing Date : 1990-10-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION (3.75mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
A Leuprolide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Leuprolide, including repackagers and relabelers. The FDA regulates Leuprolide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Leuprolide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Leuprolide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Leuprolide supplier is an individual or a company that provides Leuprolide active pharmaceutical ingredient (API) or Leuprolide finished formulations upon request. The Leuprolide suppliers may include Leuprolide API manufacturers, exporters, distributors and traders.
click here to find a list of Leuprolide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Leuprolide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Leuprolide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Leuprolide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Leuprolide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Leuprolide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Leuprolide suppliers with NDC on PharmaCompass.
We have 14 companies offering Leuprolide
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?